|
SV Bio, Mayo Clinic join forces
01-22-2013
EDIT CONNECT
SHARING OPTIONS:
ROCHESTER, Minn.—Mayo Clinic
and Silicon Valley Biosystems (SV Bio) have announced the establishment of a
strategic collaboration for whole genome
diagnostics and interpretation at two
sites: the Mayo Clinic Center for Individualized Medicine and Mayo Medical
Laboratories.
"At Mayo Clinic, we are
committed to integrating genomic medicine into the continuum of care for all of
our
patients," Gianrico Farrugia, M.D., director of the Mayo Clinic Center for
Individualized Medicine, said in a press release. "The Individualized
Medicine
Clinic represents one of Mayo's bold steps toward realizing the promise of
these game-changing technologies and toward offering new hope to
patients,
including those with cancer and diagnostic dilemmas."
Per the agreement, SV Bio's
proprietary genome interpretation solution and Mayo Clinic's genome reference
library will be brought together in hopes of increasing accessibility to
and
clinical use of next-generation sequencing for patients. SV Bio will make
available its clinical genome interpretation services and clinical
decision
support interfaces to Mayo Clinic, and the Center for Individualized Medicine
will provide clinical and laboratory support and expertise. No
financial
details were disclosed.
"Every human disease has a
genetic component but, to date,
medical providers have not been able to fully
utilize this information to improve clinical outcomes. With the SV Bio
platform, we've made the
translation to a single assay — a full human genome —
with the diagnostics rapidly and precisely happening in silico," Dietrich Stephan, Ph.D.,
founder, president and CEO
of SV Bio, said in a statement.
SV Bio's process is fully
computerized and automated, allowing for clinically actionable genome interpretation
in a matter of minutes rather than weeks. While genome sequencing
is gaining
popularity as the cost continues to drop, the volume of data that results
remains an issue in terms of managing, interpreting and making use
of it across
the board. SV Bio's technology evaluates a patient's genome at the point of
care and distills it, providing physicians with concise,
actionable reports
that allow for more informed decisions, and the partners will seek to unlock
the potential of next-generation sequencing and make
these technologies
available for all patients.
"In our laboratories, we are
rapidly adopting and
implementing next-generation sequencing as a platform upon
which we will be providing cutting-edge genome-based testing," Franklin
Cockerill, M.D.,
president of Mayo Medical Laboratories, noted in a press
release. "This collaboration with SV Bio furthers our mission of bringing the
latest
diagnostic technologies to health care providers around the world."
"We are now able to take data
from any next-generation sequencer and determine with clinical-grade
sensitivity and specificity which variants within a patient's DNA sequence are
influencing a disease or condition, and rapidly provide a report for the
clinician that is clear and actionable," said Stephan. "This level of
speed,
accuracy and integration into the clinical work flow is not only a first for
molecular testing, but also a sea change in the application of
next-generation
sequencing with no compromise of quality in clinical diagnostics."
SOURCE: SV Bio press release Code: E01221300 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|